Emerging drugs for idiopathic pulmonary fibrosis

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Expert Opinion on Emerging Drugs

• Publication date

  2005-10-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14728214.10.4.707PMID 16262559
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Induction of Epithelial-Mesenchymal Transition in Alveolar Epithelial Cells by Transforming Growth Factor-β1 : Potential Role in Idiopathic Pulmonary Fibrosis

  2005cited by this paper
• Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase‐9 expression in a human xenograft model of prostate cancer

  2005cited by this paper
• Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

  2005cited by this paper
• The absence of reactive oxygen species production protects mice against bleomycin-induced pulmonary fibrosis

  2005cited by this paper
• Modulation of prosurvival signaling in fibroblasts by a protein kinase inhibitor protects against fibrotic tissue injury.

  2005cited by this paper
• Eicosanoids: mediators and therapeutic targets in fibrotic lung disease.

  2005cited by this paper
• Tumor Necrosis Factor–α Overexpression in Lung Disease

  2005cited by this paper
• Hydrogen peroxide is a diffusible paracrine signal for the induction of epithelial cell death by activated myofibroblasts

  2005cited by this paper
• Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis.

  2005cited by this paper
• Reversible drug‐induced interstitial pneumonitis following imatinib mesylate therapy

  2005cited by this paper
• Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor.

  2005cited by this paper
• TGF-ß Signaling in Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia

  2004cited by this paper
• A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.

  2004cited by this paper
• Modulation of PDGF-C and PDGF-D expression during bleomycin-induced lung fibrosis.

  2004cited by this paper
• Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis.

  2004cited by this paper
• Mechanisms of pulmonary fibrosis.

  2004influential reference
• NOX enzymes and the biology of reactive oxygen

  2004cited by this paper
• Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis.

  2004cited by this paper
• Fibrotic disease and the TH1/TH2 paradigm

  2004cited by this paper
• Idiopathic pulmonary fibrosis: emerging concepts on pharmacotherapy

  2004cited by this paper
• Transforming the TGFbeta pathway: convergence of distinct lead generation strategies on a novel kinase pharmacophore for TbetaRI (ALK5).

  2004cited by this paper
• Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts.

  2004cited by this paper
• Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches.

  2004influential reference
• Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.

  2004cited by this paper
• Interstitial pneumonitis during imatinib therapy

  2004cited by this paper
• Fibrotic disease and the T(H)1/T(H)2 paradigm.

  2004cited by this paper
• Synthesis and Activity of New Aryl‐ and Heteroaryl‐Substituted 5,6‐Dihydro‐4H‐pyrrolo[1,2‐b]pyrazole Inhibitors of the Transforming Growth Factor‐β Type I Receptor Kinase Domain.

  2004cited by this paper
• Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals

  2004cited by this paper
• Corrigendum to “Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFβ receptor kinase (TβRI)”: [Bioorg. Med. Chem. Lett. 13 (2003) 4355]

  2004cited by this paper
• Activation of the Pro-survival Phosphatidylinositol 3-Kinase/AKT Pathway by Transforming Growth Factor-β1 in Mesenchymal Cells Is Mediated by p38 MAPK-dependent Induction of an Autocrine Growth Factor*

  2004influential reference
• Demystifying idiopathic interstitial pneumonia.

  2003cited by this paper
• Smad-dependent and Smad-independent pathways in TGF-β family signalling

  2003cited by this paper
• Acute Respiratory Failure after Interferon-γ Therapy of End-Stage Pulmonary Fibrosis

  2003cited by this paper
• Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFbeta receptor kinase (TbetaRI).

  2003cited by this paper
• Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia.

  2003cited by this paper
• Prostaglandin E2 inhibits fibroblast to myofibroblast transition via E. prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation.

  2003cited by this paper
• Tetrathiomolybdate therapy protects against bleomycin-induced pulmonary fibrosis in mice.

  2003cited by this paper
• Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling.

  2003cited by this paper
• Overexpression of tumor necrosis factor-alpha diminishes pulmonary fibrosis induced by bleomycin or transforming growth factor-beta.

  2003cited by this paper
• Intratracheal gene transfer of decorin reduces subpleural fibroproliferation induced by bleomycin.

  2003cited by this paper
• Tetrathiomolybdate anticopper therapy for Wilson's disease inhibits angiogenesis, fibrosis and inflammation

  2003cited by this paper
• Successful shape-Based virtual screening: The discovery of a potent inhibitor of the type I TGFβ receptor kinase (TβRI)

  2003cited by this paper
• Imatinib mesylate-induced interstitial pneumonitis.

  2003cited by this paper
• Repression of Bleomycin-Induced Pneumopathy by TNF

  2003cited by this paper
• Adenoviral gene transfer of connective tissue growth factor in the lung induces transient fibrosis.

  2003cited by this paper
• Myofibroblast Differentiation by Transforming Growth Factor-β1 Is Dependent on Cell Adhesion and Integrin Signaling via Focal Adhesion Kinase*

  2003influential reference
• Acute respiratory failure after interferon-gamma therapy of end-stage pulmonary fibrosis.

  2003cited by this paper
• Smad-dependent and Smad-independent pathways in TGF-beta family signalling.

  2003cited by this paper
• A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level.

  2002cited by this paper
• BOSENTAN THERAPY FOR PULMONARY ARTERIAL HYPERTENSION

  2002cited by this paper
• Pathogenesis of fibrosis: role of TGF-beta and CTGF.

  2002cited by this paper
• Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice.

  2002influential reference
• Myofibroblasts and mechano-regulation of connective tissue remodelling

  2002cited by this paper
• Effect of pirfenidone against vanadate-induced kidney fibrosis in rats.

  2002cited by this paper
• Prostaglandin E2 synthesis and suppression of fibroblast proliferation by alveolar epithelial cells is cyclooxygenase-2-dependent.

  2002cited by this paper
• TGF- 1 as an Enhancer of Fas-Mediated Apoptosis of Lung Epithelial Cells

  2002cited by this paper
• Bosentan therapy for pulmonary arterial hypertension.

  2002cited by this paper
• TGF-beta 1 as an enhancer of Fas-mediated apoptosis of lung epithelial cells.

  2002cited by this paper
• Mice lacking Smad3 are protected against cutaneous injury induced by ionizing radiation.

  2002cited by this paper
• Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis.

  2002cited by this paper
• Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome.

  2002cited by this paper
• Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock.

  2002cited by this paper
• Pirfenidone Blocks the In Vitro and In Vivo Effects of Staphylococcal Enterotoxin B

  2002cited by this paper
• Human antitransforming growth factor beta(2) monoclonal antibody--a new modulator of wound healing in trabeculectomy: a randomized placebo controlled clinical study.

  2002influential reference
• Clinical significance of histological classification of idiopathic interstitial pneumonia

  2002cited by this paper
• Usual Interstitial Pneumonia: Histologic Study of Biopsy and Explant Specimens

  2002cited by this paper
• Protection from pulmonary fibrosis in leukotriene-deficient mice.

  2002cited by this paper
• Pirfenidone effectively reverses experimental liver fibrosis.

  2002cited by this paper
• Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production.

  2002cited by this paper
• Imatinib mesylate--a new oral targeted therapy.

  2002cited by this paper
• American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors

  2002cited by this paper
• American thoracic society/European respiratory society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias

  2002influential reference
• Prostaglandin E(2) inhibits fibroblast chemotaxis.

  2001cited by this paper
• Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis.

  2001cited by this paper
• Is Smad3 a major player in signal transduction pathways leading to fibrogenesis?

  2001cited by this paper
• Attenuation of lung inflammation and fibrosis in interferon-gamma-deficient mice after intratracheal bleomycin.

  2001cited by this paper
• Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its Pathogenesis and Implications for Therapy

  2001cited by this paper
• TNF-alpha stimulates activation of pro-MMP2 in human skin through NF-(kappa)B mediated induction of MT1-MMP.

  2001cited by this paper
• Copper Control as an Antiangiogenic Anticancer Therapy: Lessons from Treating Wilson's Disease

  2001cited by this paper
• Pirfenidone Inhibits Dimethylnitrosamine‐Induced Hepatic Fibrosis In Rats

  2001cited by this paper
• Idiopathic pulmonary fibrosis.

  2001cited by this paper
• Meeting report: signaling schemes for TGF-beta.

  2001cited by this paper
• Histopathologic variability in usual and nonspecific interstitial pneumonias.

  2001cited by this paper
• Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival.

  2001cited by this paper
• Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1.

  2001cited by this paper
• Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis.

  2001cited by this paper
• Effects of pirfenidone on vascular smooth muscle cell proliferation and intimal hyperplasia following arterial balloon injury.

  2001cited by this paper
• Human myofibroblastic hepatic stellate cells express Ca(2+)-activated K(+) channels that modulate the effects of endothelin-1 and nitric oxide.

  2001cited by this paper
• Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?

  2001cited by this paper
• Type II alveolar epithelial cells and interstitial fibroblasts express connective tissue growth factor in IPF.

  2001cited by this paper
• Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin‐diabetic rats

  2001cited by this paper
• Meeting Report: Signaling Schemes for TGF-β

  2001cited by this paper
• Role of apoptosis and transforming growth factor beta1 in fibroblast selection and activation in systemic sclerosis.

  2000cited by this paper
• Apoptosis of lung epithelial cells in response to TNF-alpha requires angiotensin II generation de novo.

  2000cited by this paper
• Percutaneous in vivo gene transfer to the peripheral lungs using plasmid-liposome complexes.

  2000cited by this paper
• Tumor Necrosis Factor Alpha Inhibits Type I Collagen Synthesis through Repressive CCAAT/Enhancer-Binding Proteins

  2000cited by this paper
• Localization of endothelin receptors in bleomycin-induced pulmonary fibrosis in the rat

  2000cited by this paper
• Ras‐dependent and ‐independent regulation of reactive oxygen species by mitogenic growth factors and TGF‐β1

  2000cited by this paper
• The acute respiratory distress syndrome.

  2000cited by this paper
• Interleukin-1β and Tumor Necrosis Factor-α Decrease Collagen Synthesis and Increase Matrix Metalloproteinase Activity in Cardiac Fibroblasts In Vitro

  2000cited by this paper

• Opposite effects of systemic and local conditional CD11c+ myeloid cell depletion during bleomycin‐induced inflammation and fibrosis in mice

  2024cites this paper
• Genotoxicity evaluation of self-assembled-micelle inhibitory RNA-targeting amphiregulin (SAMiRNA-AREG), a novel siRNA nanoparticle for the treatment of fibrotic disease

  2021cites this paper
• CX3CL1 and CX3CR1 could be a relevant molecular axis in the pathophysiology of idiopathic pulmonary fibrosis

  2020cites this paper
• Protective Effects of Nintedanib against Polyhexamethylene Guanidine Phosphate-Induced Lung Fibrosis in Mice

  2018cites this paper
• Kallistatin protects against bleomycin-induced idiopathic pulmonary fibrosis by inhibiting angiogenesis and inflammation.

  2017cites this paper
• Overexpression of OSM and IL-6 impacts the polarization of pro-fibrotic macrophages and the development of bleomycin-induced lung fibrosis

  2017cites this paper
• The Investigations of the Effect of In-Vitro Combination Treatment: Curcumin, Aspirin, and Sulforaphane on Idiopathic Pulmonary Fibrosis

  2016cites this paper
• Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case report

  2016cites this paper
• Oxidative Modifications of Protein Tyrosyl Residues Are Increased in Plasma of Human Subjects with Interstitial Lung Disease.

  2016cites this paper
• cAMP mediated regulation of fibroblast to myofibroblast differentiation in idiopathic pulmonary fibrosis

  2016cites this paper
• Plasminogen Activator Inhibitor-1 Suppresses Profibrotic Responses in Fibroblasts from Fibrotic Lungs*

  2015cites this paper
• Translational Research in Acute Lung Injury and Pulmonary Fibrosis Linking progression of fibrotic lung remodeling and ultrastructural alterations of alveolar epithelial type II cells in the amiodarone mouse model

  2015cites this paper
• Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis

  2015cites this paper
• A translational preclinical model of interstitial pulmonary fibrosis and pulmonary hypertension: mechanistic pathways driving disease pathophysiology

  2014influential citation
• Integrated analyses identify the involvement of microRNA-26a in epithelial–mesenchymal transition during idiopathic pulmonary fibrosis

  2014cites this paper
• Dual Targeting of MEK and PI3K Pathways Attenuates Established and Progressive Pulmonary Fibrosis

  2014cites this paper
• Méthodes de traitement de la fibrose pulmonaire idiopathique

  2013cites this paper
• BET Bromodomain Proteins Mediate Downstream Signaling Events following Growth Factor Stimulation in Human Lung Fibroblasts and Are Involved in Bleomycin-Induced Pulmonary Fibrosis

  2013cites this paper
• PAI‐1 promotes the accumulation of exudate macrophages and worsens pulmonary fibrosis following type II alveolar epithelial cell injury

  2012cites this paper
• Protective roles of Cordyceps on lung fibrosis in cellular and rat models

  2012cites this paper
• The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial

  2011cites this paper
• Idiopathic Pulmonary Fibrosis

  2011cites this paper
• Phosphodiesterase 6 subunits are expressed and altered in idiopathic pulmonary fibrosis

  2010cites this paper
• SNAI transcription factors mediate epithelial–mesenchymal transition in lung fibrosis

  2009cites this paper
• Chapter 28 To Market, To Market — 2008

  2009cites this paper
• Potential of imatinib mesylate as a novel treatment for pulmonary fibrosis

  2008cites this paper
• The role of urokinase in idiopathic pulmonary fibrosis and implication for therapy

  2008cites this paper
• Effects of the Protein Kinase Inhibitor, Imatinib Mesylate, on Epithelial/Mesenchymal Phenotypes: Implications for Treatment of Fibrotic Diseases

  2007cites this paper
• New Insights into the Pathogenesis and Treatment of Idiopathic Pulmonary Fibrosis: A Potential Role for Stem Cells in the Lung Parenchyma and Implications for Therapy

  2007cites this paper
• Current and emerging drugs for idiopathic pulmonary fibrosis

  2007cites this paper
• Recent advances in idiopathic pulmonary fibrosis.

  2007cites this paper
• Pathogenetic pathways and novel pharmacotherapeutic targets in idiopathic pulmonary fibrosis.

  2007cites this paper
• Idiopathic pulmonary fibrosis

  2007cites this paper
• Role of Phosphodiesterases in Idiopathic Pulmonary Fibrosis

  2006cites this paper
• Idiopathic pulmonary fibrosis: an update.

  2006influential citation
• Overview of Lung Transplantation and Criteria for Selection of Candidates

  2006cites this paper
• Usual Interstitial Pneumonia

  2006cites this paper
• Idiopathic Pulmonary Fibrosis

  2003cites this paper
• Application of

  year unknowncites this paper